JP2003504316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003504316A5 JP2003504316A5 JP2001508313A JP2001508313A JP2003504316A5 JP 2003504316 A5 JP2003504316 A5 JP 2003504316A5 JP 2001508313 A JP2001508313 A JP 2001508313A JP 2001508313 A JP2001508313 A JP 2001508313A JP 2003504316 A5 JP2003504316 A5 JP 2003504316A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- region
- gene
- protein
- recombinant adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 23
- 241000701161 unidentified adenovirus Species 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 101800001643 6K protein Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 102000000311 EC 3.5.4.1 Human genes 0.000 description 1
- 108010080611 EC 3.5.4.1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34760499A | 1999-07-02 | 1999-07-02 | |
| US09/347,604 | 1999-07-02 | ||
| PCT/US2000/017856 WO2001002540A2 (en) | 1999-07-02 | 2000-06-28 | Adenoviral vectors for treating disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003504316A JP2003504316A (ja) | 2003-02-04 |
| JP2003504316A5 true JP2003504316A5 (ru) | 2006-03-23 |
Family
ID=23364433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001508313A Pending JP2003504316A (ja) | 1999-07-02 | 2000-06-30 | 疾患を処置するためのアデノウイルスベクター |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1218527A2 (ru) |
| JP (1) | JP2003504316A (ru) |
| CN (1) | CN1357050A (ru) |
| AU (1) | AU781775B2 (ru) |
| CA (1) | CA2373352A1 (ru) |
| WO (1) | WO2001002540A2 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2439185A1 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constructs |
| CN117363655A (zh) * | 2005-04-07 | 2024-01-09 | 宾夕法尼亚大学托管会 | 增强腺相关病毒载体功能的方法 |
| CN101979606A (zh) * | 2010-11-01 | 2011-02-23 | 陕西师范大学 | 一种以腺病毒表达系统产生的人逆转录泡沫病毒载体 |
| CN105274142B (zh) * | 2014-06-25 | 2018-12-04 | 中国科学院广州生物医药与健康研究院 | 复制型重组人55型腺病毒载体及其制备方法和应用 |
| CN104946602A (zh) * | 2015-06-11 | 2015-09-30 | 华中科技大学同济医学院附属同济医院 | 具有肿瘤组织靶向性和抑癌基因修复性的重组溶瘤腺病毒Ad5-P16及其应用 |
| EA202090548A1 (ru) * | 2017-09-01 | 2020-06-23 | Инпротер Апс | Вакцина для применения в профилактике и/или лечении заболевания |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| MX2022005369A (es) * | 2019-11-06 | 2022-08-08 | Memgen Inc | Adenovirus oncoliticos de replicacion mejorada. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6780406B1 (en) * | 1994-03-21 | 2004-08-24 | The Regents Of The University Of Michigan | Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene |
| PT1071805E (pt) * | 1998-04-24 | 2011-10-04 | Onyx Pharma Inc | Vectores adenovirais para tratamento de doença |
| US6303362B1 (en) * | 1998-11-19 | 2001-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Adenoviral vector and methods for making and using the same |
-
2000
- 2000-06-28 CA CA002373352A patent/CA2373352A1/en not_active Abandoned
- 2000-06-28 WO PCT/US2000/017856 patent/WO2001002540A2/en active IP Right Grant
- 2000-06-28 AU AU60578/00A patent/AU781775B2/en not_active Ceased
- 2000-06-28 CN CN00809311A patent/CN1357050A/zh active Pending
- 2000-06-28 EP EP00946890A patent/EP1218527A2/en not_active Withdrawn
- 2000-06-30 JP JP2001508313A patent/JP2003504316A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU96112150A (ru) | Рекомбинантный аденовирусный вектор и способы его применения | |
| Mukaida et al. | Cooperative interaction of nuclear factor-kappa B-and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. | |
| US20010053768A1 (en) | Gene therapy using replication competent targeted adenoviral vectors | |
| JP2002512785A5 (ru) | ||
| JP2003504316A5 (ru) | ||
| JP2005505286A5 (ru) | ||
| Qian et al. | Therapy of cancer by cytokines mediated by gene therapy approach | |
| EP1369487A3 (en) | Recombinant vectors derived from adenovirus for use in gene therapy | |
| WO2005121343A1 (fr) | Construction d'une recombinaison d'adenovirus oncolytique exprimant de facon specifique un facteur immunomodulateur gm-csf dans des cellules tumorales et utilisations correspondantes | |
| Luo et al. | Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene | |
| Braciak et al. | Construction of recombinant human type 5 adenoviruses expressing rodent IL-6 genes. An approach to investigate in vivo cytokine function. | |
| RU2006145306A (ru) | Аденовирусный/альфавитный гибридный вектор для эффективного введения и экспрессии терапевтических генов в опухолевые клетки | |
| JP2003528604A5 (ru) | ||
| JP2007525949A (ja) | 自己プロセッシング性ペプチド切断部位を含む細胞特異的複製適格ウィルス・ベクター | |
| JP2004501650A5 (ru) | ||
| Kim et al. | Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in α-fetoprotein-producing human liver cancer cells | |
| CA2404235A1 (en) | Cell-specific adenovirus vectors comprising an internal ribosome entry site | |
| JP2004511203A5 (ru) | ||
| Curtin et al. | Turning the gene tap off; implications of regulating gene expression for cancer therapeutics | |
| KR970706397A (ko) | IV a2 유전자가 불활성화된 결손 재조합 아데노바이러스(DEFECTIVE RECOMBINANT ADENOVIRUSES WITH AN INACTIVATED IV a2 GENE) | |
| CA2383372A1 (en) | Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression | |
| US20020086004A1 (en) | Use of a defective recombinant adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension | |
| Nunokawa et al. | Expression of human inducible nitric oxide synthase is regulated by both promoter and 3′-regions | |
| Marr et al. | A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor α expressed from an adenovirus vector induces an antitumor response with reduced toxicity | |
| Rhoades et al. | The adenoviral transcription factor, E1A 13S, trans-activates the human tumor necrosis factor-α promoter |